CLINICAL TRIALS PROFILE FOR ZANUBRUTINIB
✉ Email this page to a colleague
All Clinical Trials for ZANUBRUTINIB
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02569476 ↗ | BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies | Completed | BeiGene | Phase 1 | 2016-01-13 | This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies. |
| NCT02795182 ↗ | Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies | Completed | BeiGene | Phase 1 | 2016-06-29 | This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in participants with B-cell lymphoid malignancies. |
| NCT02914938 ↗ | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Recruiting | Clinipace LTD | Phase 1 | 2016-10-01 | A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL |
| NCT02914938 ↗ | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Recruiting | MEI Pharma, Inc. | Phase 1 | 2016-10-01 | A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL |
| NCT03053440 ↗ | A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) | Active, not recruiting | BeiGene | Phase 3 | 2017-01-25 | This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 (Zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia. |
| NCT03088878 ↗ | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | Recruiting | California Institute for Regenerative Medicine (CIRM) | Phase 1/Phase 2 | 2018-01-03 | This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells. |
| NCT03088878 ↗ | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | Recruiting | Oncternal Therapeutics, Inc | Phase 1/Phase 2 | 2018-01-03 | This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZANUBRUTINIB
Condition Name
Clinical Trial Locations for ZANUBRUTINIB
Trials by Country
Clinical Trial Progress for ZANUBRUTINIB
Clinical Trial Phase
Clinical Trial Sponsors for ZANUBRUTINIB
Sponsor Name
